Needham & Company LLC Issues Positive Forecast for Privia Health Group (NASDAQ:PRVA) Stock Price

Privia Health Group (NASDAQ:PRVA) had its price target increased by analysts at Needham & Company LLC from $25.00 to $30.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 17.83% from the stock’s previous close.

Several other brokerages have also recently weighed in on PRVA. Macquarie initiated coverage on Privia Health Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $25.00 price target for the company. JMP Securities reissued a “market outperform” rating and set a $26.00 target price on shares of Privia Health Group in a research report on Friday, February 14th. JPMorgan Chase & Co. raised their price target on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, November 29th. Truist Financial upped their price objective on shares of Privia Health Group from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Stephens reiterated an “overweight” rating and set a $26.00 price objective on shares of Privia Health Group in a research report on Thursday, January 2nd. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Privia Health Group currently has a consensus rating of “Buy” and an average price target of $25.50.

Privia Health Group Stock Up 5.8 %

NASDAQ PRVA opened at $25.46 on Friday. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of 254.63, a PEG ratio of 3.47 and a beta of 0.87. Privia Health Group has a twelve month low of $15.92 and a twelve month high of $26.04. The stock has a fifty day simple moving average of $22.30 and a 200 day simple moving average of $20.55.

Hedge Funds Weigh In On Privia Health Group

Institutional investors have recently modified their holdings of the company. Mackenzie Financial Corp grew its position in Privia Health Group by 87.2% in the 4th quarter. Mackenzie Financial Corp now owns 72,391 shares of the company’s stock valued at $1,415,000 after purchasing an additional 33,728 shares during the period. Neo Ivy Capital Management lifted its stake in shares of Privia Health Group by 81.5% in the fourth quarter. Neo Ivy Capital Management now owns 6,540 shares of the company’s stock valued at $127,000 after buying an additional 2,936 shares in the last quarter. PharVision Advisers LLC acquired a new position in shares of Privia Health Group during the fourth quarter valued at about $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Privia Health Group by 13.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 939,170 shares of the company’s stock worth $18,361,000 after acquiring an additional 114,647 shares in the last quarter. Finally, Two Sigma Advisers LP acquired a new stake in shares of Privia Health Group in the 4th quarter worth about $940,000. 94.48% of the stock is owned by institutional investors and hedge funds.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.